U.S. markets open in 5 hours 29 minutes
  • S&P Futures

    4,401.50
    +6.75 (+0.15%)
     
  • Dow Futures

    34,737.00
    +47.00 (+0.14%)
     
  • Nasdaq Futures

    15,088.75
    +15.25 (+0.10%)
     
  • Russell 2000 Futures

    2,196.10
    +4.40 (+0.20%)
     
  • Crude Oil

    68.07
    -0.08 (-0.12%)
     
  • Gold

    1,816.50
    +2.00 (+0.11%)
     
  • Silver

    25.47
    +0.01 (+0.04%)
     
  • EUR/USD

    1.1853
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.1840
    0.0000 (0.00%)
     
  • Vix

    17.74
    -0.30 (-1.66%)
     
  • GBP/USD

    1.3923
    +0.0038 (+0.27%)
     
  • USD/JPY

    109.5690
    +0.1010 (+0.09%)
     
  • BTC-USD

    38,872.48
    +1,047.56 (+2.77%)
     
  • CMC Crypto 200

    962.14
    +35.38 (+3.82%)
     
  • FTSE 100

    7,118.02
    -5.84 (-0.08%)
     
  • Nikkei 225

    27,728.12
    +144.04 (+0.52%)
     

Why Pacira (PCRX) Could Be an Impressive Growth Stock

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Pacira BioSciences, Inc. PCRX. This firm, which is in the Medical - Drugs industry, saw EPS growth of 60.6% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 49.9%. Furthermore, the long-term growth rate is currently an impressive 33.5%, suggesting pretty good prospects for the long haul.

Pacira Pharmaceuticals, Inc. Price and Consensus

Pacira Pharmaceuticals, Inc. Price and Consensus
Pacira Pharmaceuticals, Inc. Price and Consensus

Pacira Pharmaceuticals, Inc. price-consensus-chart | Pacira Pharmaceuticals, Inc. Quote

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by approximately 16%. Thanks to this rise in earnings estimates, PCRX has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider PCRX. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for PCRX as well.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pacira Pharmaceuticals, Inc. (PCRX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research